The assessment of cardiotoxicity is important in the early stages of drug discovery to eliminate potentially toxic compounds from further development. This is critical to reduce the inefficiencies and high costs associated with compounds that fail during cardiac safety assessment.

Learn about in vitro cardiotoxicity assays that use biologically relevant 3D cell-based models that are suitable for high-throughput screening.

Learn More